- Home
- NBIX vs SNN Comparison
NBIX vs SNN Comparison
Compare NBIX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | SNN |
|---|---|---|
| Founded | 1992 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 14.0B |
| IPO Year | 1996 | 1999 |
Fundamental Metrics
Financial Performance| Metric | NBIX | SNN |
|---|---|---|
| Price | $155.51 | $33.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 4 |
| Target Price | ★ $173.79 | $32.83 |
| AVG Volume (30 Days) | ★ 969.9K | 476.9K |
| Earning Date | 10-28-2025 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | 12.44 | ★ 59.91 |
| EPS | ★ 4.19 | 0.56 |
| Revenue | $2,682,700,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $23.76 | $7.78 |
| Revenue Next Year | $18.01 | $5.13 |
| P/E Ratio | $37.10 | ★ $29.10 |
| Revenue Growth | ★ 19.61 | 5.35 |
| 52 Week Low | $84.23 | $23.69 |
| 52 Week High | $157.67 | $38.79 |
Technical Indicators
Market Signals| Indicator | NBIX | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 48.01 |
| Support Level | $150.26 | $32.68 |
| Resistance Level | $154.35 | $33.56 |
| Average True Range (ATR) | 4.16 | 0.41 |
| MACD | 1.07 | 0.14 |
| Stochastic Oscillator | 93.25 | 78.51 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.